XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Phase II study of second line capecitabine plus oxaliplatin (XELOX) in patients with advanced
biliary tract carcinoma after failure of gemcitabine-based chemotherapy.